The European Response to the CCR5 Patent
The European Response to the CCR5 Patent
This chapter discusses the patenting of the CCR5 gene in Europe. It compares and contrasts the practices of the United States Patent and Trademark Office (USPTO) with the European Patent Office (EPO) with regard to gene patenting. It also focuses on the anatomy of opposing a European patent and offers an informative glimpse into the world of patent litigation. A contrast between the USPTO and the EPO is informative since it points out that there are alternatives: questions of human value are embedded differently in various legal regimes. The situation in which the US finds itself is not inevitable.
Keywords: European Patent Office, United States Patent and Trademark Office, gene patenting in Europe, patent litigation, Big Pharma, Euroscreen
MIT Press Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
Please, subscribe or login to access full text content.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.
